San Francisco, CA -- (SBWIRE) -- 09/25/2014 -- CMEA Capital portfolio company Neos Therapeutics, Inc. (“Neos” or “the Company”), a specialty pharmaceutical company with highly differentiated proprietary oral drug delivery technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced that it has acquired all commercialization rights to its Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended Release Suspension Product from partners Chiesi USA, Inc., and Coating Place, Inc. This product is a generic equivalent to the Tussionex® brand drug and provides relief of upper respiratory and cough symptoms from allergy / cold in adults and children above six years of age.
Neos also announced that it has settled all pending litigation related to its amphetamine polistirex orally disintegrating tablet (known as NT-0202, which treats ADHD). This drug is positioned to be the first-ever, extended release orally disintegrating tablet for treating ADHD. Shire LLC had filed suit on April 11, 2013 against Neos, alleging that the latter infringed on US Patent Nos. RE 42096 and 41148. The two parties have now entered into an agreement that provides the Company with a license to make, market, and sell NT-0202 with royalties through the expiration of the patents.
About Neos Therapeutics
Neos Therapeutics, Inc. is a fully integrated specialty pharmaceutical company. The Company is initially focusing on ADHD with three proprietary products in late-stage development that provide patient-friendly dosage forms incorporating controlled and extended release oral disintegrating tablets (ODT) and liquid suspensions. In addition, Neos manufactures and markets a generic of Tussionex® for the treatment of cough and cold. The Company’s products are developed and manufactured using its proprietary and patented ion resin technology. For more information, visit www.neostx.com.
This press release contains certain forward-looking statements that include projections and may also include words such as may, will, expects, believes, anticipates, plans, estimates, seeks, could, intends, and other similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.
About CMEA Capital
CMEA Capital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.
Press Relations Contact:
Victoria Jenks
victoria@cmea.com
ph: 415-352-1520